Literature DB >> 22101572

Prognostic significance of peritoneal washing cytology in patients with gastric cancer.

S D Lee1, K W Ryu, B W Eom, J H Lee, M C Kook, Y-W Kim.   

Abstract

BACKGROUND: Positive peritoneal washing cytology is a poor prognostic factor in patients with gastric cancer. The right therapeutic approach for this condition has not been well documented.
METHODS: Patients who underwent surgery for gastric cancer with suspected serosal invasion and peritoneal washing cytology at the Korean National Cancer Centre between May 2001 and December 2009 were included in this retrospective study. Clinicopathological factors and overall survival were analysed with respect to the cytological results and presence of peritoneal metastases. Prognostic factors were analysed in patients with positive cytology but without overt peritoneal metastases.
RESULTS: A total of 1072 patients were included in the analysis, of whom 900 had negative cytology (C0 group) and 172 had positive cytology (C1 group). No peritoneal metastases (P0) were found in 830 patients (92·2 per cent) in the C0 group. Peritoneal metastases (P1) were found in 76 patients (44·2 per cent) in the C1 group. Median overall survival times in the P0 C1, P1 C0 and P1 C1 subgroups were 20·0, 14·0 and 10·0 months respectively. Multivariable analysis of the P0 C1 subgroup revealed that clinical N0-2 category and gastric resection were significantly associated with better prognosis (median survival 24·0 versus 13·0 months for N0-2 versus N3, and 21·0 versus 4·0 months for resected versus non-resected).
CONCLUSION: Positive washing cytology in patients with gastric cancer is a negative prognostic factor for patients with, as well as those without, overt peritoneal metastases. Resection is an option in patients with clinical stage N0-2 disease without peritoneal metastases but with a positive washing cytology finding.
Copyright © 2011 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 22101572     DOI: 10.1002/bjs.7812

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  31 in total

1.  The current role of staging laparoscopy in oesophagogastric cancer.

Authors:  L Convie; R J Thompson; R Kennedy; W D B Clements; P D Carey; J A Kennedy
Journal:  Ann R Coll Surg Engl       Date:  2015-03       Impact factor: 1.891

2.  The clinical significance of potentially curative resection for gastric cancer following the clearance of free cancer cells in the peritoneal cavity by induction chemotherapy.

Authors:  Masaki Aizawa; Atsushi Nashimoto; Hiroshi Yabusaki; Satoru Nakagawa; Atsushi Matsuki; Keiichi Homma; Takashi Kawasaki
Journal:  Surg Today       Date:  2014-07-16       Impact factor: 2.549

3.  Prognostic role of gastrectomy in patients with gastric cancer with positive peritoneal cytology.

Authors:  Okihide Suzuki; Minoru Fukuchi; Erito Mochiki; Toru Ishiguro; Jun Sobajima; Hisashi Onozawa; Hideko Imaizumi; Youichi Kumagai; Hiroyuki Baba; Kensuke Kumamoto; Yoshitaka Tsuji; Keiichiro Ishibashi; Hideyuki Ishida
Journal:  Int Surg       Date:  2014 Nov-Dec

4.  The survival and prognosticators of peritoneal cytology-positive gastric cancer patients who received upfront gastrectomy and subsequent S-1 chemotherapy.

Authors:  Kazuki Kano; Toru Aoyama; Yukio Maezawa; Tetsushi Nakajima; Kosuke Ikeda; Takanobu Yamada; Tsutomu Sato; Takashi Oshima; Yasushi Rino; Munetaka Masuda; Takashi Ogata; Haruhiko Cho; Takaki Yoshikawa
Journal:  Int J Clin Oncol       Date:  2017-04-29       Impact factor: 3.402

5.  Conversion Surgery for Gastric Cancer with Peritoneal Metastasis Based on the Diagnosis of Second-Look Staging Laparoscopy.

Authors:  Masaki Nakamura; Toshiyasu Ojima; Mikihito Nakamori; Masahiro Katsuda; Toshiaki Tsuji; Keiji Hayata; Tomoya Kato; Hiroki Yamaue
Journal:  J Gastrointest Surg       Date:  2018-09-27       Impact factor: 3.452

6.  Risk of peritoneal metastases in patients who had negative peritoneal staging and received therapy for localized gastric adenocarcinoma.

Authors:  Dilsa Mizrak Kaya; Graciela M Nogueras-González; Kazuto Harada; Fatemeh G Amlashi; Sinchita Roy-Chowdhuri; Jeannelyn S Estrella; Prajnan Das; Jeffrey H Lee; Brian Weston; Manoop S Bhutani; Aurelio Matamoros; Irene Thomas; Quan Lin; Brian D Badgwell; Jaffer A Ajani
Journal:  J Surg Oncol       Date:  2017-12-04       Impact factor: 3.454

Review 7.  Intraperitoneal free cancer cells in gastric cancer: pathology of peritoneal carcinomatosis and rationale for intraperitoneal chemotherapy/hyperthermic intraperitoneal chemotherapy in gastric cancer.

Authors:  Zhong-He Ji; Kai-Wen Peng; Yan Li
Journal:  Transl Gastroenterol Hepatol       Date:  2016-09-19

8.  DNA diagnosis of peritoneal fluid cytology test by CDO1 promoter DNA hypermethylation in gastric cancer.

Authors:  Hideki Ushiku; Keishi Yamashita; Akira Ema; Naoko Minatani; Mariko Kikuchi; Ken Kojo; Keigo Yokoi; Toshimichi Tanaka; Nobuyuki Nishizawa; Satoru Ishii; Kei Hosoda; Hiromitsu Moriya; Hiroaki Mieno; Natsuya Katada; Shiro Kikuchi; Hiroshi Katoh; Masahiko Watanabe
Journal:  Gastric Cancer       Date:  2017-02-27       Impact factor: 7.370

9.  Is there a role for treatment-oriented surgery in stage IV gastric cancer? A systematic review.

Authors:  Sarah Molfino; Zeno Ballarini; Federico Gheza; Nazario Portolani; Gian Luca Baiocchi
Journal:  Updates Surg       Date:  2018-07-23

10.  Prognosis and treatment of patients with positive peritoneal cytology in advanced gastric cancer.

Authors:  Francesco Frattini; Stefano Rausei; Corrado Chiappa; Francesca Rovera; Luigi Boni; Gianlorenzo Dionigi
Journal:  World J Gastrointest Surg       Date:  2013-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.